Instil Bio (Nasdaq: TIL) trims Q1 2026 loss and extends cash runway beyond 2027
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Instil Bio reported first quarter 2026 results showing a much smaller loss and a solid cash position while it evaluates potential acquisitions and in-licensing opportunities for new therapeutics. As of March 31, 2026, the company held about $74.7 million in cash, cash equivalents, restricted cash and marketable securities and expects this to fund its current operating plan beyond 2027.
Net loss for the quarter was $4.2 million, or $0.62 per share, compared with $28.2 million, or $4.32 per share, a year earlier. On a non-GAAP basis, excluding stock-based compensation and restructuring and impairment charges, net loss was $2.2 million, or $0.32 per share, versus $8.6 million, or $1.32 per share.
Operating expenses declined sharply, with research and development at $0.7 million, general and administrative at $5.3 million, and restructuring and impairment charges at $1.0 million, all down significantly from the prior year period. Management highlighted an ongoing strategic shift toward building a focused pipeline through externally sourced assets, while cautioning there is no assurance any transaction will occur.
Positive
- Cash runway beyond 2027: Instil Bio held approximately $74.7 million in cash, cash equivalents, restricted cash and marketable securities as of March 31, 2026 and expects this to fund its current operating plan beyond 2027.
- Substantial reduction in losses: GAAP net loss narrowed to $4.2 million from $28.2 million year over year, while non-GAAP net loss declined to $2.2 million from $8.6 million.
- Lower operating expenses: Research and development, general and administrative, and restructuring and impairment charges all decreased significantly versus the prior-year quarter, indicating a much leaner cost structure.
Negative
- None.
Insights
Instil Bio cut losses sharply, preserved cash runway beyond 2027, and is actively scouting external assets.
Instil Bio ended March 31, 2026 with about $74.7 million in cash, equivalents, restricted cash and marketable securities, and indicates this should fund its operating plan beyond 2027. This is meaningful for a development-stage biotech without product revenue.
Net loss improved to $4.2 million from $28.2 million, driven by much lower research and development, general and administrative, and restructuring and impairment charges. Non-GAAP net loss of $2.2 million removes stock-based compensation and restructuring to show a leaner ongoing cost base.
Management is evaluating acquisitions and in-licensing to assemble a “focused, high-quality” pipeline, but explicitly notes there is no assurance any transaction will result. Subsequent filings may provide details if a specific deal is approved or otherwise requires disclosure.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Cash and securities: $74.7M
Net loss: $4.2M
Non-GAAP net loss: $2.2M
+5 more
8 metrics
Cash and securities
$74.7M
Cash, cash equivalents, restricted cash and marketable securities as of March 31, 2026
Net loss
$4.2M
GAAP net loss for three months ended March 31, 2026
Non-GAAP net loss
$2.2M
Non-GAAP net loss for three months ended March 31, 2026
Total operating expenses
$7.0M
Operating expenses for three months ended March 31, 2026
Research and development
$0.7M
R&D expense for three months ended March 31, 2026
General and administrative
$5.3M
G&A expense for three months ended March 31, 2026
Restructuring and impairment
$1.0M
Restructuring and impairment charges for three months ended March 31, 2026
Stockholders’ equity
$110.7M
Stockholders’ equity as of March 31, 2026
Key Terms
non-GAAP net loss, restructuring and impairment charges, stock-based compensation expense, marketable securities, +2 more
6 terms
non-GAAP net loss financial
"These non-GAAP financial measures include non-GAAP net loss and non-GAAP net loss per share"
Non-GAAP net loss is a company’s reported loss that has been adjusted by removing certain costs or one-time items that the company believes hide its core operating performance. Think of it like looking at a household budget but excluding an unusual repair or sale; it can show a clearer view of everyday results, which helps investors judge ongoing profitability, but it can also omit real expenses so it should be compared with the standard GAAP loss.
restructuring and impairment charges financial
"Restructuring and impairment charges were $1.0 million for the three months ended March 31, 2026"
Restructuring and impairment charges are accounting entries that reflect costs from reorganizing a business and from recognizing that assets are worth less than previously recorded. Think of restructuring as paying to rearrange or shrink your operations (like closing a shop or laying off staff), and impairment as writing down the value of an asset that no longer earns as much as expected (like admitting an old machine is obsolete). They matter to investors because they reduce reported profits, can signal management action or deeper problems, and affect future cash flows and valuation.
stock-based compensation expense financial
"excluding non-cash stock-based compensation expense and restructuring and impairment charges"
Stock-based compensation expense is the value that a company records when it gives employees or executives shares or options to buy shares as part of their pay. It matters because it shows the true cost of paying employees this way, which can affect the company's profits and how investors see its financial health.
marketable securities financial
"cash, cash equivalents, restricted cash and marketable securities, which consisted of $5.0 million in cash and cash equivalents"
Marketable securities are financial assets — such as publicly traded stocks, bonds, and short-term government bills — that a company can quickly sell for cash at a known price. Investors watch them because they show how much ready cash a company can access without selling core operations, like keeping money in a highly liquid savings account versus being tied up in a house, and they affect short-term risk, financial flexibility, and balance-sheet strength.
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
cash runway financial
"Instil expects that its cash, cash equivalents, restricted cash and marketable securities as of March 31, 2026 will enable it to fund its current operating plan beyond 2027"
Cash runway is the amount of time a company can continue operating using its available cash before needing additional funding or generating enough revenue. It’s like a countdown showing how long a business can keep running with its current funds. Knowing the cash runway helps investors assess the company's financial health and whether it has enough resources to reach its goals or needs to find more support soon.
Earnings Snapshot
Net loss: $4.2M
Quarter ended March 31, 2026
Net loss
$4.2M
vs. $28.2M prior-year quarter
Non-GAAP net loss
$2.2M
vs. $8.6M prior-year quarter
Operating expenses
$7.0M
vs. $30.6M prior-year quarter
Cash and securities
$74.7M
vs. $76.3M at December 31, 2025
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 15, 2026
(Exact name of registrant as specified in its Charter)
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(Address of Principal Executive Offices) | (Zip Code) | |||||||
(972 ) 499-3350
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On May 15, 2026 , Instil Bio, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended March 31, 2026 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.
The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) | Exhibits | ||||
Exhibit No. | Description | |||||||
99.1 | Press release, dated May 15, 2026 | |||||||
104 | The cover page of this report has been formatted in Inline XBRL. | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Instil Bio, Inc. | ||||||||||||||||||||
Dated: | By: | /s/ Sandeep Laumas, M.D. | ||||||||||||||||||
Sandeep Laumas, M.D. | ||||||||||||||||||||
Chief Financial Officer and Chief Business Officer (Principal Financial Officer and Principal Accounting Officer) | ||||||||||||||||||||
Instil Bio Reports First Quarter 2026 Financial Results and
Provides Corporate Update
DALLAS, TX, May 15, 2026 (GLOBE NEWSWIRE) - Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its first quarter 2026 financial results and provided a corporate update.
Recent Highlights
•Instil is evaluating potential acquisitions and in-licensing that may provide access to promising novel therapeutic candidates
•Cash position of approximately $74.7 million as of March 31, 2026 expected to fund current operating plan beyond 2027
“We continue to make progress refining Instil’s strategy and positioning the company for its next phase of growth,” said Bronson Crouch, Chief Executive Officer, Instil Bio. “We are actively evaluating a range of acquisition and in-licensing opportunities, with a focus on assets that align with our capabilities and offer the potential to create long-term value. With a strong balance sheet, we are well positioned to act with discipline and flexibility as we work to build a focused, high-quality pipeline and advance new treatment options for patients.”
There can be no assurance that any transaction will result from these efforts, nor as to the timing of any such outcome. Instil does not intend to provide further updates unless and until a specific transaction is approved or disclosure is otherwise deemed appropriate.
First Quarter 2026 Financial and Operating Results:
As of March 31, 2026, Instil had approximately $74.7 million in total cash, cash equivalents, restricted cash and marketable securities, which consisted of $5.0 million in cash and cash equivalents, $0.1 million in restricted cash and $69.5 million in marketable securities, compared to $76.3 million in total cash, cash equivalents, restricted cash and marketable securities, which consisted of $6.6 million in cash and cash equivalents, $0.2 million in restricted cash, and $69.5 million in marketable securities, as of December 31, 2025. Instil expects that its cash, cash equivalents, restricted cash and marketable securities as of March 31, 2026 will enable it to fund its current operating plan beyond 2027.
Research and development expenses were $0.7 million for the three months ended March 31, 2026, compared to $5.4 million for the three months ended March 31, 2025.
General and administrative expenses were $5.3 million for the three months ended March 31, 2026, compared to $9.1 million for the three months ended March 31, 2025.
Restructuring and impairment charges were $1.0 million for the three months ended March 31, 2026, compared to $16.1 million for the three months ended March 31, 2025.
Net loss per share, basic and diluted was $0.62 for the three months ended March 31, 2026, compared to $4.32 for the three months ended March 31, 2025. Non-GAAP net loss per share, basic and diluted
was $0.32 for the three months ended March 31, 2026, compared to $1.32 for the three months ended March 31, 2025.
Note Regarding Use of Non-GAAP Financial Measures
In this press release, Instil has presented certain financial information that has not been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). These non-GAAP financial measures include non-GAAP net loss and non-GAAP net loss per share, which are defined as net loss and net loss per share, respectively, excluding non-cash stock-based compensation expense and restructuring and impairment charges. Instil believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Instil’s financial performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of Instil’s operating results. In addition, these non-GAAP financial measures are among the indicators Instil’s management uses for planning purposes and to measure Instil’s performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by Instil may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Please refer to the below reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures.
About Instil Bio
Instil Bio, Inc. is a biotechnology company focused on identifying and advancing innovative therapeutics. For more information, visit www.instilbio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “exploring,” “future,” “intends,” “may,” “plans,” “potential,” “projects,” “targets,” “next phase” and “will” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include express or implied statements concerning Instil's expectations regarding its next phase of strategic development and pursuing potential acquisition and in-licensing opportunities; Instil's expectations regarding its capital position, resources, and balance sheet, including its cash runway; and other statements that are not historical fact. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements, including risks and uncertainties related to the next phase of strategic development, pursuing potential transactions to acquire companies or in-license product candidates and the sufficiency of Instil's cash resources, as well as interest rates, inflation, tariffs, international conflicts and other factors which could materially and adversely affect Instil’s business and operations, and other risks and uncertainties affecting Instil's plans and strategy, including those discussed in the section titled “Risk Factors” in Instil's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 to be filed with the SEC, as well as Instil's other filings with the SEC. These forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as the date hereof, and Instil disclaims any obligation to update these statements except as may be required by law.
Contacts:
Investor Relations: 1-972-499-3350 investorrelations@instilbio.com www.instilbio.com | ||
INSTIL BIO, INC.
SELECTED FINANCIAL DATA
(Unaudited; in thousands, except share and per share amounts)
Selected Condensed Consolidated Balance Sheet Data
| March 31, 2026 | December 31, 2025 | ||||||||||
| Cash, cash equivalents, restricted cash and marketable securities | $ | 74,694 | $ | 76,295 | |||||||
| Total assets | $ | 200,428 | $ | 203,523 | |||||||
| Total liabilities | $ | 89,730 | $ | 89,657 | |||||||
| Stockholders’ equity | $ | 110,698 | $ | 113,866 | |||||||
Condensed Consolidated Statements of Operations
| Three Months Ended March 31, | |||||||||||
| 2026 | 2025 | ||||||||||
| Operating expenses: | |||||||||||
| Research and development | $ | 669 | $ | 5,371 | |||||||
| General and administrative | 5,349 | 9,109 | |||||||||
| Restructuring and impairment charges | 992 | 16,082 | |||||||||
| Total operating expenses | 7,010 | 30,562 | |||||||||
| Loss from operations | (7,010) | (30,562) | |||||||||
| Interest income | 678 | 1,175 | |||||||||
| Interest expense | (1,552) | (1,098) | |||||||||
| Other rental income | 2,242 | 2,242 | |||||||||
| Gain on contract termination | 1,620 | — | |||||||||
| Other (expense) income, net | (182) | 43 | |||||||||
| Net loss | $ | (4,204) | $ | (28,200) | |||||||
| Net loss per share, basic and diluted | $ | (0.62) | $ | (4.32) | |||||||
| Weighted-average shares used in computing net loss per share, basic and diluted | 6,781,976 | 6,532,658 | |||||||||
INSTIL BIO, INC.
Reconciliation of GAAP to Non-GAAP Net Loss and Net Loss per Share
(Unaudited; in thousands, except share and per share amounts)
| Three Months Ended March 31, | |||||||||||
| 2026 | 2025 | ||||||||||
| Net loss | $ | (4,204) | $ | (28,200) | |||||||
| Adjustments: | |||||||||||
| Non-cash stock-based compensation expense | 985 | 3,495 | |||||||||
| Restructuring and impairment charges | 992 | 16,082 | |||||||||
| Non-GAAP net loss | $ | (2,227) | $ | (8,623) | |||||||
| Net loss per share, basic and diluted | $ | (0.62) | $ | (4.32) | |||||||
| Adjustments: | |||||||||||
| Non-cash stock-based compensation expense per share | 0.15 | 0.54 | |||||||||
| Restructuring and impairment charges per share | 0.15 | 2.46 | |||||||||
| Non-GAAP net loss per share, basic and diluted* | $ | (0.32) | $ | (1.32) | |||||||
| Weighted-average shares outstanding, basic and diluted | 6,781,976 | 6,532,658 | |||||||||
* Non-GAAP net loss per share, basic and diluted may not total due to rounding.
###
FAQ
How much cash does Instil Bio (TIL) have and how long will it last?
Instil Bio reported about $74.7 million in cash, cash equivalents, restricted cash and marketable securities as of March 31, 2026. The company expects this balance to fund its current operating plan beyond 2027, providing a multi-year financial runway for its strategic initiatives.
What was Instil Bio’s net loss in the first quarter of 2026?
Instil Bio recorded a GAAP net loss of $4.2 million, or $0.62 per share, for the quarter ended March 31, 2026. This compares with a net loss of $28.2 million, or $4.32 per share, in the same quarter of 2025.
What are Instil Bio’s non-GAAP results for Q1 2026?
Non-GAAP net loss, excluding stock-based compensation and restructuring and impairment charges, was $2.2 million for Q1 2026. Non-GAAP net loss per share was $0.32, compared with $1.32 in the prior-year period, highlighting reduced underlying operating losses.
How did Instil Bio’s operating expenses change year over year?
For Q1 2026, Instil Bio’s total operating expenses were $7.0 million, down from $30.6 million a year earlier. Research and development, general and administrative, and restructuring and impairment charges all declined significantly versus the first quarter of 2025.
Is Instil Bio pursuing acquisitions or in-licensing deals?
Instil Bio is actively evaluating potential acquisitions and in-licensing opportunities for promising novel therapeutic candidates. Management emphasizes there is no assurance any transaction will result, and it does not plan further updates unless a specific deal is approved or disclosure is otherwise appropriate.
What were Instil Bio’s key balance sheet figures at March 31, 2026?
As of March 31, 2026, Instil Bio reported $200.4 million in total assets and $89.7 million in total liabilities. Stockholders’ equity was approximately $110.7 million, reflecting the company’s net asset position after a period of reduced operating losses.